A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT07931495
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07931495
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China, Japan, Poland, Puerto Rico, Romania, Slovakia, Türkiye
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07931495. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-06-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- Acronym
- AMBITION 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Zenagamtide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07931495- Content hash
ede824f29fc78d46f23175da69d2c5ae276f492a6aec3984470ed0638e58df99